Skip to Content
 

E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us

    News: Breast Cancer

    Study identifies protein’s role in chemotherapy resistance

    Friday, July 21st, 2017

    Researchers at Vanderbilt University Medical Center (VUMC) have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have mutations in the tumor suppressor gene BRCA2. The protein, RADX, is a DNA-binding protein. It regulates the activity of an enzyme called RAD51, which helps repair tumor-promoting […]

    Arteaga to direct UT Southwestern cancer center

    Thursday, July 13th, 2017

    Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center […]

    VICC experts to discuss high risk breast cancer at free seminar June 6

    Friday, May 26th, 2017

    Vanderbilt-Ingram Cancer Center (VICC), in collaboration with the Hereditary Cancer Program and the Vanderbilt Breast Center, will host a free seminar, “Are You at High Risk for Breast Cancer?” This interactive program to be held Tuesday, June 6, 5:30 – 7:30 p.m., at Vanderbilt Health One Hundred Oaks, 719 Thompson Lane, is open to anyone […]

    Polarity protein role in cell survival

    Thursday, April 27th, 2017

    Cell survival is dependent upon regulation of numerous proteins, both cytosolic and membrane bound. Reporting in Nature Communications, Mukhtar Ahmed, Ph.D., and Ian Macara, Ph.D., identified an unexpected link between cell survival and the polarized delivery of proteins to the surface of mammary epithelial cells. The Par3 protein plays a central role in polarity. It […]

    Study examines new breast cancer drug combination

    Thursday, April 27th, 2017

    A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy. The study, published in Cancer Research, was led by first author Valerie Jansen, M.D., Ph.D., instructor in Medicine. Valerie […]

    Vanderbilt’s Pietenpol joins Sledge as a Chief Scientific Advisor for Susan G. Komen

    Thursday, April 6th, 2017

    Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center (VUMC) and director of Vanderbilt-Ingram Cancer Center (VICC), has been named a Chief Scientific Advisor (CSA) for the nonprofit breast cancer organization Susan G. Komen. Jennifer Pietenpol, Ph.D. She joins George Sledge Jr., M.D., professor of Medicine at Stanford University Medical Center, […]

    Breast cancer program lands new research grants

    Friday, March 24th, 2017

    Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. The grants totaling more than $3 million will fund mechanistic science and clinical trials designed to test novel therapy combinations and determine why some forms of breast cancer become resistant […]

    Chance to sing for the Pope motivates cancer patient

    Thursday, January 26th, 2017

    Cancer patient Sharon Edwards will lift her voice toward what she hopes is a better year when she sings for Pope Francis later this month. “I used to be a soprano until radiation turned me into an alto,” she said, attempting to hold back a tear with humor. She doesn’t always succeed. It’s hard not […]

    Targeting the “un-targetable”

    Thursday, December 1st, 2016

    Triple negative breast cancers (TNBC) are so named because they lack common genetic “target” mutations that can be easily treated with specific cancer drugs. However, in a recent study published in Molecular Cancer Therapeutics, Deborah Lannigan, Ph.D., and colleagues investigated a new target involved in TNBC called RSK. They demonstrated that RSK can help cancers […]

    Screening mammograms now offered at four locations

    Thursday, October 13th, 2016

    One in eight women will be diagnosed with breast cancer in their lifetime and those cancers are often detected through screening mammograms. A mammogram is a low-dose X-ray of the breast that enables an imaging specialist to look for changes in breast tissue that could indicate cancer. The American Cancer Society, the National Comprehensive Cancer […]

    Next Page »

    E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us